DBV Technologies (DBVT)

Executive Summary

DBV Technologies is a clinical-stage biopharmaceutical company pioneering epicutaneous immunotherapy (EPIT) via its proprietary VIASKIN® patch platform, primarily targeting peanut allergy. The company's lead product, Viaskin Peanut, has completed Phase 3 trials, including the PEPITES and REALISE studies, demonstrating a favorable safety profile and efficacy in desensitizing patients. DBV is preparing to resubmit a Biologics License Application (BLA) to the FDA, following a prior rejection in 2020 related to manufacturing concerns, which the company has since addressed. If approved, Viaskin Peanut would offer a non-invasive, at-home treatment alternative to oral immunotherapy, potentially capturing a significant share of the large peanut allergy market. The company also has early-stage programs for cow's milk allergy and whooping cough. With a valuation of approximately $939 million, DBV remains a high-risk, high-reward investment, contingent on regulatory success. Key upcoming catalysts include the BLA resubmission, FDA acceptance, and potential approval, which could drive significant value.

Upcoming Catalysts (preview)

• H2 2026BLA Resubmission for Viaskin Peanut80% success
• Q1 2027FDA Acceptance of Resubmitted BLA70% success
• H1 2027Phase 2/3 Data Readout for Viaskin Milk50% success